• Hua Medicine

  Participated · Series C · Apr 2016

  Hua Medicine is a Shanghai-based, clinical-stage drug development company focused on novel therapies for Type 2 diabetes and levodopa-induced dyskinesia in Parkinson’s disease. The company has worldwide rights to two novel assets, the most advanced being dorzagliatin (HMS5552). Dorzagliatin is described as a first-in-class, 4th-generation glucokinase activator that aims to treat impaired blood glucose sensor function. The drug is in two Phase III trials in China: a monotherapy study and a combination therapy study with metformin. Hua announced a combined Series D & Series E financing intended to fully fund completion of those Phase 3 trials and a commercial launch in China. The company was founded by entrepreneurs and international investment firms and positions dorzagliatin as a potential disease-modifying treatment for Type 2 diabetes. Hua Medicine is a clinical-stage, innovative drug development company focused on novel therapies for the treatment of diabetes and central nervous system disorders. Its lead program is HMS5552, a new 4th-generation glucokinase activator (GKA) for type 2 diabetes. The company plans to use the new financing to complete long-term Phase 2 clinical trials and to accelerate Phase 3 development of HMS5552, alongside advancing additional novel assets in its pipeline. Hua is led by CEO Li Chen and is based in Shanghai, China. It expects to finish a multicenter, 12-week Phase 2 trial of HMS5552 in diabetic patients by mid-year, with topline results available by the end of 2016. Hua Medicine is a Shanghai, China–based clinical-stage biotech led by Dr. Li Chen developing novel therapies for Type 2 diabetes and CNS disorders. Its most advanced program is HMS5552 (Sinogliatin), an oral 4th‑generation glucokinase activator (GKA) about to enter Phase 2 trials in China. The company has also internally developed earlier-stage CNS compounds targeting a validated CNS target for indications including Parkinson’s disease–associated dyskinesia and depressive disorder. Hua recently closed a $25M Series B to fund clinical and preclinical programs. Planned uses of proceeds include catalyzing Phase 2 development of HMS5552, advancing GKA therapies in the U.S., developing an IND candidate for a novel CNS asset, and sponsoring long‑term preclinical studies to prepare for future Phase 3 trials.

• Xtreme Power Conversion

  Participated · Equity · Jul 2011

  Xtreme Power designs, engineers, manufactures, and operates integrated energy storage and power management systems branded as Dynamic Power Resources (DPR). The DPR platform provides fast-responding, configurable digital systems that can time-shift power and simultaneously perform multiple services demanded by the energy market. Customers include Independent Power Producers, Transmission and Distribution Utilities, and Commercial and Industrial end users. The company was founded in November 2004 and is headquartered in Kyle, Texas, with manufacturing at multiple U.S. locations and representation in Austin, Maui, Houston, Washington, D.C., and Chicago. Financially, Xtreme Power had raised more than $50 million since founding and recently closed an additional financing. The company is described as rapidly expanding in the article. Xtreme Power is a Kyle, Texas–based company that engineers, manufactures and operates integrated power management and energy storage systems for renewable energy and micro-grid applications. The company closed a $29.5M financing round on July 27, 2010. The investment was co-led by Bessemer Venture Partners and The Dow Chemical Company (through its venture capital group), with participation from existing backers SAIL Venture Partners, POSCO ICT and SkyLake & Co. In conjunction with the funding, Umesh Padval, a Partner with Bessemer Venture Partners, and Walter Schindler, Managing Partner at SAIL Venture Partners, joined Xtreme Power’s board of directors. The financing will support the company’s technology development, production expansion and large-scale power projects. Proceeds are intended to advance deployment and development of its integrated power management and energy storage systems.

• Cleantech Group

  Participated · Equity · Feb 2010

  The Cleantech Group is a global research and advisory firm focused on cleantech innovation. It provides research and advisory services to corporations, investors, and government agencies on cleantech trends and opportunities. The company closed a $3.2M Series C, its third round of equity financing, to expand its capabilities. The new funds will be used to enhance the Group’s global research offerings and to inform and advise corporate, investor, and government clients. As part of its growth the company added several executive and board members, naming Sheeraz Haji president and adding George Hornig of Credit Suisse to the board. Other appointments included Richard Youngman as Managing Director, Europe and Vice President, Global Research; Greg Neichin as Vice President, Advisory Services; and Nicholas Parker as Co-founder and Executive Chairman.

No current team members are available.